Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Clin Cancer Res. 2017 Jan 17;23(13):3385–3395. doi: 10.1158/1078-0432.CCR-16-1904

Figure 2. Cytotoxicity of SL-101 against myeloid leukemia cell lines in vitro.

Figure 2

(A) Percentages of CD123+ and CD131+ cells are shown for myeloid leukemia cell lines. (B) Annexin-V−/DAPI− viable cells were measured by flow cytometry after treatment with SL-101 at indicated doses for 48 hours. The cell counts were normalized to those of untreated samples. (C) Correlation analysis was performed between expression of IL-3 receptor subunits and IC50 values of SL-101 calculated by using Calcusyn software. (D) Expression of CD123 was measured in parental and CD123-overexpressing (K562CG-CD123) K562 cells. Cells were left untreated or exposed to indicated concentrations of SL-101 for 48 hours, and viable cell counts were determined as described in (B).